Repros Issues Added Info Confirming Success for Study ZA-302, Says SPA Met Co-Primary Endpoints
September 18, 2013 at 10:28 AM EDT
Repros Therapeutics Inc.® (Nasdaq: RPRX )today reported additional topline results for study ZA-302, the second pivotal efficacy study for Androxal®. The results of both pivotal studies, ZA-301 and ZA-302, have met the SPA co-primary endpoints as defined by the FDA. Study ZA-302 had no detected site anomalies. Additional data which
